Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Pierre Fabre

Finance Watch: Lightstone Ventures Closes $375m Fund To Back Early Stage Biotechs

Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.

Financing Innovation

Ontozry Wins English Funding For Drug-Resistant Epilepsy

Heath technology assessment body NICE estimates that around 17,000 patients would be eligible for treatment with Arvelle’s drug.

United Kingdom Health Technology Assessment

GNT Eyes Unmet Need As Novel Ischemic Stroke Therapy Moves To Phase III

Korea's GNT Pharma is set to take its first-in-class, multi-targeted stroke therapy Nelonemdaz into Phase III, raising hopes for a new treatment that could sharply reduce disabilities and death in stroke patients. 

South Korea Neurology

Hugel Expects Acquisition By GS Consortium Won’t Deter Growth Strategy

Hugel says its longer-term global growth strategy will remain intact after a major acquisition of the Korean medical aesthetics company by a consortium including GS Group.

South Korea M & A
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Services
    • Pharmacy Services, PBMs
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Pierre Fabre Medicament S.A.
UsernamePublicRestriction

Register